A Malaysian farmer is growing musk melons for a third of the price of Japanese grown ones. Source: Reuters
A Malaysian farmer is growing musk melons for a third of the price of Japanese grown ones. Source: Reuters
Gasoline outages are tearing through the Southeast as panicked motorists fill up their vehicles and reserve containers, spooked by last week’s cyberattack on the nation’s largest fuel pipeline.
AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of "a-" (Excellent) of United Kingdom Mutual War Risks Association Limited (UK War Risks or the Association) (United Kingdom). The outlook of these Credit Ratings (ratings) is stable.
The "21 CFR Part 11 Compliance for SaaS/Cloud Applications" conference has been added to ResearchAndMarkets.com's offering.
Hydrobuilder Holdings LLC ("Hydrobuilder Holdings" or "the Company") a leading omni-channel retailer of specialty agriculture and hydroponics equipment and supplies, today announced the appointment of Daniel Laughlin as Senior Vice President of Corporate Development. In this new position, Daniel will oversee the Company’s acquisition activities.
New Tuition Support Benefit Encourages Pursuit of EducationATLANTA, May 12, 2021 (GLOBE NEWSWIRE) -- Grady Health, one of the largest safety net health systems in the U.S., has selected Fiducius as its provider of education assistance and student loan benefits for its more than 8,000 employees. Financial stress, compounded by the pressures of student loan debt and the Covid-19 pandemic, is an increasing source of hospitals’ on-going recruiting and retention challenges. To address these issues, Grady offers the Loan Relief benefit to provide student loan education and support to all employees and their family members, and will soon launch a new Tuition Support benefit to help eligible employees pursue their continuing education goals. "We’re committed to supporting the wellbeing of all our employees by providing a complete total rewards package,” said Baldomero Silvo, Vice President Total Rewards at Grady. “With our new Tuition Support benefit, we are eliminating any obstacles for those employees who want to continue their education. In our search for a solution, we discovered Fiducius was the only partner capable of enabling eligible employees to use ‘forgivable debt’ to finance their education. Employees win with significantly better financial health, while Grady reduces our program cost. And for those employees who have student loan debt, we’re providing the financial education, tools and support they need to tackle it head on with the Loan Relief benefit.” As part of the Loan Relief benefit, all employees and family members have unlimited access to the Student Loan Financial Planning process, a combination of proprietary technology and professional Advisors. This process provides each employee with the expert guidance needed to enable informed decisions and action. “For healthcare employees, work is much more than a job… it’s a true calling. A desire and commitment to serve others. Nothing should get in the way of this calling, including on-going education and student loan debt,” said David Cross, EVP of Sales and Chief Marketing Officer at Fiducius. “Grady is doing incredible work by providing benefits that empower employees to advance their careers and take control of their student loans, transforming lives in the process.” Added Ross Weintraub, Fiducius Senior Manager, Business Development and Sales Operations, “The benefits team at Grady is simply top-notch in their pursuit of the best benefits to support their staff. We’re honored that they again turned to Fiducius, in this case to help employees achieve their educational goals. ” About Grady Health System Grady Health System consists of the 953-bed Grady Memorial Hospital, six neighborhood health centers, Crestview Health & Rehabilitation Center, and Children’s Healthcare of Atlanta at Hughes Spalding, which is operated as a Children’s affiliate. With its nationally acclaimed emergency services, Grady is Atlanta’s premier Level 1 trauma center. Grady EMS serves as the 911 ambulance provider for the city of Atlanta, South Fulton County communities, and numerous counties across Georgia. It also operates the state’s first Mobile Stroke Unit, taking cutting-edge pre-hospital care directly to patients. Grady’s American Burn Association/American College of Surgeons verified Burn Center is one of only two in the state. And the Marcus Stroke and Neuroscience Center is a Joint Commission designated Advanced Comprehensive Stroke Center. Other key services/distinctions include Grady’s Regional Perinatal Center with its Neonatal Intensive Care Unit, Georgia’s first Cancer Center for Excellence, The Avon Comprehensive Breast Center, the Georgia Comprehensive Sickle Cell Center, and the Ponce de Leon Center – one of the top HIV/AIDS outpatient clinics in the country. Grady is one of an elite group of hospitals to earn the Baby-Friendly USA international recognition as a Baby-Friendly Designated birth facility. Grady has earned the prestigious Stage 7 on the HIMSS Analytics Electronic Medical Record Adoption Model – Georgia’s first adult acute care hospital to earn the highest rating for improving patient care and safety through health information technology. To learn more about , please visit www.gradyhealth.org. About Fiducius, LLC Providing student loan and education assistance benefits since 2011, Fiducius enables employers to achieve recruiting, retention and productivity goals, while empowering employees to achieve financial wellness. Fiducius offers a complete range of voluntary and sponsored benefits, including Loan Relief, Loan Contribution, Tuition Reimbursement and Tuition Contribution (529 plans). Its proprietary Student Loan Financial Planning approach combines expert Advisors and advanced technology to ensure all employees receive the best option for their unique situations. Fiducius works with more than 2,500 employers, including more than 100 healthcare systems, hospitals and other providers. For more information, visit: www.getfiducius.com CONTACT: Jermaine L. Hood Grady Health System, Human Resources Benefits Administration JHOOD@gmh.edu David Cross Fiducius LLC, EVP of Sales & CMO email@example.com
The "Network Telemetry - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Atlanta, May 12, 2021 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) today announced the launch of a new white paper, “Rheumatic Diseases in America: Confronting the Challenge,” which provides an overview of the current health care challenges facing the rheumatic disease community and highlights the importance of receiving timely and appropriate treatment from a rheumatology health professional. Released during Arthritis Awareness Month, the white paper aims to educate policymakers, health care professionals, members of the media and the general public about rheumatic diseases, which affect approximately 54 million adults and at least 300,000 children in the United States alone. “Rheumatology is a broad discipline that covers a wide variety of diseases that affect a person’s joints, musculoskeletal systems, immune system and many other organs,” said Dr. Suleman Bhana, Chair of the ACR’s Communications and Marketing Committee. “With this white paper, we aim to create an accessible, introductory resource for those interested in learning more about rheumatic disease, current treatment options, and the health care and lifestyle challenges patients with rheumatic disease face.” The white paper is written and designed to appeal to multiple audiences and consists of four key sections: I. Rheumatology 101 This section provides an introduction to what a rheumatic disease is, describes the role of a rheumatologist, and discusses the importance of early and appropriate treatment. Patients and their family members – particularly those who may have been recently diagnosed with a rheumatic disease – may find this section helpful in understanding what to expect after a diagnosis. Health care professionals may also find this section to be an important resource for conversations with patients to reinforce the importance of timely and accurate diagnosis, and why coordinating care between specialists is so important. There are over 100 different rheumatic diseases and conditions, some of the most common include: rheumatoid arthritis, lupus, gout, scleroderma, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and Sjögren’s syndrome. This white paper discusses what some of these diseases are and how they affect different parts of the body. II. Rheumatic Diseases: Prevalence & Impact Rheumatic diseases in America are extremely common. According to the CDC, an estimated 54 million Americans – 1 in 4 – have a doctor-diagnosed rheumatic disease and some studies have suggested that the actual number of Americans living with these diseases is even higher when accounting for symptoms reported by undiagnosed individuals. The economic toll of rheumatic diseases is also significant. The total cost of rheumatic diseases was recently estimated to be as high as $304 billion annually – greater than the total cost of cancer care in the United States. For policymakers, the media and the general public, this white paper provides useful statistics that call attention to rheumatic diseases as a public health issue, why solutions are urgently needed to improve patients’ quality of life, and why rheumatology health care professionals are uniquely equipped to help patients manage these diseases. II. Emerging Trends in Rheumatology Providers may find the white paper’s discussion of emerging trends in rheumatology – including biosimilars and telehealth – to be helpful in their practice. Rheumatology is a constantly changing field of medicine and these issues will become increasingly important for patients, providers, and the public to understand. Biosimilars (copies of biologic drugs that are intended to work in the same way as their reference products) represent a new and promising area of rheumatic disease treatment. However, educating patients and providers about their use will continue to be crucial to ensuring their uptake. While recent research has shown that rheumatologists generally have a good understanding and acceptance of biosimilar products, a recent survey found that 29 percent of rheumatic disease patients were unsure whether they had been prescribed a biosimilar drug. Telehealth, the adoption of which has been catalyzed by the COVID-19 pandemic, represents another important emerging trend in the practice of rheumatology. As many as 66 percent of rheumatic disease patients had an appointment via telehealth in 2020 and these services have been shown to especially benefit individuals with disabilities, those who are in a nursing home, and those living in an area where they would have to travel long distances for treatment. IV. Access, Affordability & Lifestyle Challenges for People Living with Rheumatic Disease People living with rheumatic diseases face a variety of access, affordability, and lifestyle challenges associated with their disease. This white paper provides an overview to the public policy issues related to these challenges such as a growing rheumatology workforce shortage, insurer practices that restrict access to care, and rising drug prices that threaten to make treatment unaffordable for many who rely on specialty medications to manage their symptoms. Solutions are needed to address these issues – and others – that affect the rheumatic disease community. This white paper presents readers with the latest opportunities to get involved with the ACR and Simple Tasks to advocate for better public policy. To download and read the white paper, CLICK HERE. # # # Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves over 7,700 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. CONTACT: Kyna Willis American College of Rheumatology (404) 929-4831 firstname.lastname@example.org
Shares of Lumentum (NASDAQ: LITE) have gotten crushed today, down by 17% as of noon EDT, after the company reported fiscal third-quarter earnings. Lumentum's top-line results and guidance disappointed investors and the company took a hit due to delays in deployments. Revenue in the fiscal third quarter was $419.5 million, which missed the consensus estimate of $434 million.
Company Announcement COPENHAGEN, Denmark; May 12, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com. Contact: Marisol Peron, Senior Vice President, Global Investor Relations & CommunicationsT: +1 609 524 0065; E: email@example.com For Investor Relations: Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: firstname.lastname@example.org The Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®. CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark Attachment 210512_CA41_Managerial Employee's Transactions
The "Medical Device Single Audit Program [MDSAP] Implementation & Participating Country Regulatory Processes: U.S., Canada, Brazil, Australia and Japan" conference has been added to ResearchAndMarkets.com's offering.
The Indonesia Data Center Market was valued at USD 1785. 2 million in 2020 and is expected to reach USD 3354. 41 million by 2026 at a CAGR of 11. 4% over the forecast period 2021 - 2026. Indonesia ranks lower in the competitive index as compared to other Southeast Asian countries.New York, May 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Indonesia Data Center Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06067814/?utm_source=GNW However, the potential commercial upside for data center players is significant. Indonesia is witnessing a growing digital economy, coupled with the rapid growth of startup companies and the ever-growing population, leading to an increase in hyper-scale data centers.- The latest research from Google and Temasek in their report economy SEA 2019 stated that the growth of the digital economy in Indonesia is expected to reach 133 million USD in the year 2025.- According to content management service HootSuite and social media marketing agency We Are Social in the report “Digital 2020”, Internet users in Indonesia have reached 175,4 million, with penetration at 64%. This means as much as 64% of the total Indonesian population of 272,1 million, is connected to the Internet. This number has since increased from the year 2019, which was 17%, or approximately 25 million people.- There is a sudden increase in the use of internet and data services, especially during the holidays, which indicates the seasonality of increased telecom data center utilization in the country. For instance, three telecommunications internet data traffic rose 57% on the first day of Eid al-Fitr 2020, followed by Telkomsel with an increase of 49.8%, and Indosat Ooredoo by 27%.- Businesses have also started adopting data-intensive applications, such as IoT, data analytics, and artificial intelligence. This translates to the surge of data exchanged and transferred and increased traffic.- Indonesia is giving a strong competition to Singapore as the hotspot for the data center in Asia. Increased investments by companies, such as Google, Alibaba, and Amazon, reflect a growing interest in Indonesia as an alternative to Singapore, which was traditionally the focus of cloud service investment because of its good fiber connectivity.- In April 2019, Amazon Web Services (AWS) announced the launch of a new cloud region in Indonesia, based in Greater Jakarta, with the new area set to comprise three availability zones. Last year, Alibaba Cloud launched a second data center in Indonesia just ten months after its first one, to double its local capacity. As it stands, Alibaba Cloud is the only global public cloud platform with regional data centers in Indonesia.- The principal factors driving the growth of COVID-19 impact on the Indonesia Data Center Market are increasing demand for digital transformation, increased investments in Data Center, growing demand for remote services and location data, and increasing need for real-time information track and monitor the COVID-19 spread.Key Market TrendsA Surge in Mobile Data and Internet Users, to Boost the Market Growth- The increasing number of internet and social media users are expected to influence the Indonesia data center market. According to StatCounter, Indonesia booked the fastest growth of the global top-ten smartphone markets in the third quarter of 2019, with shipments up 29% year-on-year. Moreover, according to We Are Social, as of October 2019, around 99% of the population in Indonesia watch videos online. In addition, about 79% of the respondents watch Vlogs too.- According to Hootsuite, one in three global internet users now use voice interfaces on their mobile phones each month, but these figures are even higher in Asia with 48% of Indonesian internet users say they used a voice interface on their phone in the past month. With a penetration rate of over 88%, Hootsuite indicated that YouTube was the most used social network in Indonesia.- Indonesia’s current e-commerce market is like China’s online marketplace beginnings, with a large pool of entrepreneurial sellers providing goods purchased mainly based on social media recommendations. Moreover, the country is Asia’s foremost mobile-first nation, with one of the highest mobile-Facebook usage rates. This is also one of the major driving factors for the growth of data centers.- The government is continuing to improve internet network across the country. This is evident by the completion of the Palapa Ring, which is an ambitious initiative to install a high-speed system with 12,000 kilometers of fiber cable, to serve as the national backbone and overcome the challenges of Indonesia’s dispersed geographical layout.Increasing Demand for Cloud Computing Fuel the Market- The deployment of data centers in Indonesia is likely to exceed supply due to the growing demand for cloud-based services, big data analytics, and IoT. Also, Cloud operators have overtaken financial service clients to be the most significant occupiers of data centers. In turn, multimedia content providers and cloud businesses drive strong demand for data center storage and networking in Indonesia.- Google Cloud announced the opening of its new Jakarta region in June 2020, bringing services closer to its Indonesian and Southeast Asian consumers. The newly launched cloud platform marks the first Google region in Indonesia and the ninth in the Asia Pacific. It offers cloud computing services, data analytics, machine learning, and security and management tools for businesses.- According to a 2019 study by Google Cloud, businesses that adopt public cloud services could add around USD 36 billion to Indonesia’s GDP between 2019 and 2023. They could also generate around 350,000 jobs across several industries. Also, Google Cloud Indonesia plans to roll out 150,000 training labs in Indonesia in 2020 to enable cloud computing training and certification for Indonesians.- Indonesia is currently home to two data centers from Alibaba Cloud and Google. Meanwhile, Amazon’s cloud subsidiary Amazon Web Services revealed that it would build a data center in 2022.Competitive LandscapeThe Indonesia Data Center Market is moderately competitive and consists of several major players. To sustain the market and retain their clients, companies are employing powerful competitive strategies; thus, intensifying competitive rivalry in the market. Some of the recent developments in the market are:- In June 2020 - DCI Indonesia launched the third data center building (JK3) and has started its operations this year and is expected to support the development of digital technology in IndonesiaReasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06067814/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Vegan Restaurateur Pinky Cole joins Yahoo Finance Live to discuss her collaboration with Incogmeato by Morningstar Farms.
The "REACH and RoHS Compliance: Protecting Revenues with Advanced Compliance" conference has been added to ResearchAndMarkets.com's offering.
House Oversight Committee questions Trump officials about response to Capitol insurrection
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Radiation Oncology Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027” LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- The Global Radiation Oncology Market is expected to grow at a CAGR of around 7.1% from 2020 to 2027 and reach the market value of over US$ 11.0 Bn by 2027. Radiation oncology, radiotherapy, or radiation therapy is a medical specialty used for the treatment of cancer. The overall technology uses the energy mostly x rays (photon) and is commonly delivered through a linear accelerator. The linear accelerator is housed within a cancer center and a multidisciplinary team comprises radiation oncologists, nurses, radiation therapists, and medical physicists. The global radiation oncology market is segmented on the basis of type, technology, application, and geography. Based on type, the market is divided across external beam radiation therapy (linear accelerators (LINAC), compact advanced radiotherapy systems), proton therapy, cyclotron, synchrotron, internal beam radiation therapy (brachytherapy, systemic beam radiation therapy, and others. By technology, the market is divided into external beam radiation therapy, (image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), stereotactic technology, proton beam therapy, 3D conformal radiotherapy (3D CRT), volumetric modulated arc therapy (VMAT), internal beam radiation therapy (low-dose rate brachytherapy, high-dose rate brachytherapy), and systemic radiation therapy. DOWNLOAD SAMPLE PAGES OF THIS REPORT@ https://www.acumenresearchandconsulting.com/request-sample/2618 Additionally, radiation oncology has applications across external beam radiation therapy including prostate cancer, breast cancer, lung cancer, head & neck cancer, colorectal cancer, and others, and internal radiation therapy including prostate cancer, gynecological cancer, breast cancer, cervical cancer, penile cancer, and others. On the basis of application, external beam radiation therapy accounted for the maximum revenue share (%) and the segment is also projected to maintain its dominance over the forecast period from 2020 to 2027. North America accounted for the maximum revenue share and the region is also projected to maintain its dominance over the forecast period from 2020 to 2027. The major economies of the region including US and Canada are the major revenue contributors. Furthermore, North America is followed by Europe in the revenue share of radiation oncology in 2019. VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/radiation-oncology-market Furthermore, Asia Pacific is projected to exhibit the fastest growth over the forecast period from 2020 to 2027. The rapidly developing economies across the region are contributing to the rapid growth during the forecast period. The increasing number of cancer cases is the major factor boosting the market growth. Additionally, the increasing spending power of residents of developing economies boosts their spending on treatment is another factor contributing to the regional market value. Some of the leading competitors are Accuray Incorporated, C.R. BARD, INC. (BD), Curium Pharma, Elekta AB, Ion Beam, Applications (IBA), Isoray Medical, Mevion Medical Systems, Inc., Nordion Inc., NTP Radioisotopes SOC Ltd., Varian Medical Systems, Inc., Viewray Technologies, Inc., and others. The major players are continuously involved in the development of advanced technologies that can overcome the drawbacks of existing ones as well as provide better imaging quality. The strategic developments undergone by the major players include mergers and acquisitions, partnerships and collaborations, and new product development. Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports Some of the key observations regarding the radiation oncology industry include: In 2021, ONCOFACTS has organized an international virtual CME (Continuing Medical Education) on ‘Practice Changing Capsule for Breast Cancer Radiation Oncology Update’ on the first Sunday of May 2021 under the aegis of Association of Radiation Oncologists of India, North Zone Chapter, and American Oncology Institute ASCOMS Hospital, Jammu.A multidisciplinary team has been developed in April 2021 to promote communication and collaboration among radiation oncology care facilities. Research from a poster presentation at the Oncology Nursing Society’s 46th Annual Congress has detailed the development and implementation of a multidisciplinary patient-centered care team at a radiation oncology outpatient clinic.RaySearch Laboratories AB (publ) has signed a sales agent agreement with Canon Medical Systems USA, Inc. in May 2021. The new agreement enables RaySearch America's salesforce to promote Canon Medical's Aquilion Large Bore CT and Celesteion PET/CT products.Ion Beam Applications S.A. (IBA) has announced that its Proteus®ONE1 compact proton therapy solution has been selected by Advocate Radiation Oncology in April 2021. This has been done in conjunction with affiliate Southwest Florida Proton for its new radiation oncology center of Advocate Radiation Oncology. INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2618 BUY THIS PREMIUM RESEARCH REPORT - https://www.acumenresearchandconsulting.com/buy-now/0/2618 Would like to place an order or any question, please feel free to contact at firstname.lastname@example.org | +1 407 915 4157 For Latest Update Follow Us: https://twitter.com/AcumenRC https://www.facebook.com/acumenresearchandconsulting https://www.linkedin.com/company/acumen-research-and-consulting
For those who want to practice a more mindful way to drink
‘This woman will not be an En Marche candidate,’ said party officials
Lo Toney, Plexo Capital Founding Managing Partner joins the Yahoo Finance Live panel to discuss the latest market action.
France's love affair with cinema threatens to be an overwhelming experience next week, when theatres finally reopen -- the scheduling nightmare of a massive backlog of 400 films.
Chelsea and Arsenal will battle it out in a Premier League London derby at Stamford Bridge this evening. Thomas Tuchel’s side are still fighting for success on three fronts, with the Blues in the FA Cup Final, Champions League Final and still seeking to secure a Premier League top-four finish.